Liposomal amphotericin B in the treatment of visceral leishmaniasis
- 1 January 1991
- journal article
- case report
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 28 (suppl B) , 111-118
- https://doi.org/10.1093/jac/28.suppl_b.111
Abstract
A case of visceral leishmaniasis unresponsive to several courses of treatment with standard drugs, was successfully cured by a 21 day course (50 mg/day) of liposomal amphotericin B (AmBisome, Vestar Inc). The dficacy of the ArnBisome formulation is supported by experimental studies on Leishmania donovani infected BALB/c mice where ED50, values of AmBisome and conventional amphotericin B were 0·15–0·25 and 0·95–4·9 mg/kg respectively. A lack of toxicity of the AmBisome formulation was noted in both studies.Keywords
This publication has 0 references indexed in Scilit: